Skip to main content
. 2017 Jun 23;12(6):e0179798. doi: 10.1371/journal.pone.0179798

Fig 4. KPC34 reduces CNS burden in mice bearing ALL.

Fig 4

  • A) Schema of treatment trial. C57/Bl6 mice were tail vein injected with B6-ALL cells. Upon engraftment, mice were treated with saline p.o. (So), saline i.p. (Si), Gemcitabine at 8.8 mg/kg i.p. (G), or KPC34 at 20 mg/kg p.o. (K). Upon onset of hind limb paralysis in control mice, all mice were imaged and euthanized.
  • B) Bioluminescent image of mice on Day 14 from injection. Red squares were used to gate leukemic infiltration within the brain.
  • C) Quantified total luminescence in brains of treated mice on Day 14. Values represent Mean + SEM. Unpaired t test was performed following one-way ANOVA. ** = p value ≤ 0.01.
  • D) Representative slides of fixed, sectioned and H+E stained brains of mice treated as indicated.